Franco Cecchi

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/3370255/publications.pdf

Version: 2024-02-01

414034 257101 9,941 34 24 32 h-index citations g-index papers 34 34 34 7713 docs citations times ranked citing authors all docs

#	Article	IF	CITATIONS
1	Use of Smartphone-operated ECG for home ECG surveillance in COVID-19 patients. European Heart Journal Digital Health, 2021, 2, 175-178.	0.7	8
2	Defining the diagnostic effectiveness of genes for inclusion in panels: the experience of two decades of genetic testing for hypertrophic cardiomyopathy at a single center. Genetics in Medicine, 2019, 21, 284-292.	1.1	54
3	Arrhythmias due to Inherited and Acquired Abnormalities of Ventricular Repolarization. Cardiac Electrophysiology Clinics, 2019, 11, 345-362.	0.7	8
4	Clinical Course and Significance of Hypertrophic Cardiomyopathy Without Left Ventricular Hypertrophy. Circulation, 2019, 139, 830-833.	1.6	43
5	Histopathological comparison of intramural coronary artery remodeling and myocardial fibrosis in obstructive versus end-stage hypertrophic cardiomyopathy. International Journal of Cardiology, 2019, 291, 77-82.	0.8	22
6	Common presentation of rare diseases: Left ventricular hypertrophy and diastolic dysfunction. International Journal of Cardiology, 2018, 257, 344-350.	0.8	19
7	Long-term Outcomes of Pediatric-Onset Hypertrophic Cardiomyopathy and Age-Specific Risk Factors for Lethal Arrhythmic Events. JAMA Cardiology, 2018, 3, 520.	3.0	78
8	International External Validation Study of the 2014 European Society of Cardiology Guidelines on Sudden Cardiac Death Prevention in Hypertrophic Cardiomyopathy (EVIDENCE-HCM). Circulation, 2018, 137, 1015-1023.	1.6	149
9	Genotype and Lifetime Burden of Disease in Hypertrophic Cardiomyopathy. Circulation, 2018, 138, 1387-1398.	1.6	468
10	Subcutaneous implantable cardioverter defibrillator in cardiomyopathies and channelopathies. Journal of Cardiovascular Medicine, 2018, 19, 633-642.	0.6	8
11	Timing of invasive septal reduction therapies and outcome of patients with obstructive hypertrophic cardiomyopathy. International Journal of Cardiology, 2018, 273, 155-161.	0.8	17
12	Effectiveness of subcutaneous implantable cardioverter-defibrillator testing in patients with hypertrophic cardiomyopathy. International Journal of Cardiology, 2017, 231, 115-119.	0.8	30
13	Cardiovascular screening in low-income settings using a novel 4-lead smartphone-based electrocardiograph (D-Heart $\hat{A}^{\text{@}}$). International Journal of Cardiology, 2017, 236, 249-252.	0.8	23
14	Reply to: Is subcutaneous implantable cardioverter-defibrillator testing effective and safe for patients with hypertrophic cardiomyopathy?. International Journal of Cardiology, 2017, 246, 55.	0.8	0
15	Pharmacological treatment of hypertrophic cardiomyopathy: current practice and novel perspectives. European Journal of Heart Failure, 2016, 18, 1106-1118.	2.9	101
16	Histological and Histometric Characterization of Myocardial Fibrosis in End-Stage Hypertrophic Cardiomyopathy. Circulation: Heart Failure, $2016, 9, .$	1.6	103
17	Impact of Genotype on the Occurrence of Atrial Fibrillation in Patients With Hypertrophic Cardiomyopathy. American Journal of Cardiology, 2016, 117, 1151-1159.	0.7	25
18	Prevalence of subcutaneous implantable cardioverter-defibrillator candidacy based on template ECG screening in patients with hypertrophic cardiomyopathy. Heart Rhythm, 2016, 13, 457-463.	0.3	46

#	Article	IF	CITATIONS
19	Recommendations for initiation and cessation of enzyme replacement therapy in patients with Fabry disease: the European Fabry Working Group consensus document. Orphanet Journal of Rare Diseases, 2015, 10, 36.	1.2	239
20	Clinical Spectrum, Therapeutic Options, and Outcome of Advanced Heart Failure in Hypertrophic Cardiomyopathy. Circulation: Heart Failure, 2015, 8, 1014-1021.	1.6	67
21	Biventricular arrhythmogenic cardiomyopathy: a paradigmatic case. ScienceOpen Research, 2015, .	0.6	0
22	Uncertain diagnosis of Fabry disease: Consensus recommendation on diagnosis in adults with left ventricular hypertrophy and genetic variants of unknown significance. International Journal of Cardiology, 2014, 177, 400-408.	0.8	119
23	Prognostic Value of Quantitative Contrast-Enhanced Cardiovascular Magnetic Resonance for the Evaluation of Sudden Death Risk in Patients With Hypertrophic Cardiomyopathy. Circulation, 2014, 130, 484-495.	1.6	783
24	2014 ESC Guidelines on diagnosis and management of hypertrophic cardiomyopathy. European Heart Journal, 2014, 35, 2733-2779.	1.0	3,469
25	Relationship of ECG findings to phenotypic expression in patients with hypertrophic cardiomyopathy: A cardiac magnetic resonance study. International Journal of Cardiology, 2013, 167, 1038-1045.	0.8	38
26	Pattern and degree of left ventricular remodeling following a tailored surgical approach for hypertrophic obstructive cardiomyopathy. Global Cardiology Science & Practice, 2012, 2012, 9.	0.3	13
27	Developmental origins of hypertrophic cardiomyopathy phenotypes: a unifying hypothesis. Nature Reviews Cardiology, 2009, 6, 317-321.	6.1	72
28	Assessment and Significance of Left Ventricular Mass by Cardiovascular Magnetic Resonance in Hypertrophic Cardiomyopathy. Journal of the American College of Cardiology, 2008, 52, 559-566.	1.2	269
29	Spatial Relationship Between Coronary Microvascular Dysfunction and Delayed Contrast Enhancement in Patients with Hypertrophic Cardiomyopathy. Journal of Nuclear Medicine, 2008, 49, 1090-1096.	2.8	68
30	Relevance of Coronary Microvascular Flow Impairment to Long-Term Remodeling and Systolic Dysfunction in Hypertrophic Cardiomyopathy. Journal of the American College of Cardiology, 2006, 47, 1043-1048.	1.2	208
31	Hypertrophic Cardiomyopathy Is Predominantly a Disease of Left Ventricular Outflow Tract Obstruction. Circulation, 2006, 114, 2232-2239.	1.6	830
32	Long-Term Effects of Surgical Septal Myectomy on Survival in Patients With Obstructive Hypertrophic Cardiomyopathy. Journal of the American College of Cardiology, 2005, 46, 470-476.	1.2	677
33	Effect of Left Ventricular Outflow Tract Obstruction on Clinical Outcome in Hypertrophic Cardiomyopathy. New England Journal of Medicine, 2003, 348, 295-303.	13.9	1,217
34	Coronary Microvascular Dysfunction and Prognosis in Hypertrophic Cardiomyopathy. New England Journal of Medicine, 2003, 349, 1027-1035.	13.9	670